KRAS-Targeting RNAi Composition for Precision mRNA Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments targeting KRAS-related diseases, including cancers and syndromes associated with KRAS mutations, hyper-activity, and over-expression.
Innovation Solution
The use of RNAi agents, specifically double-stranded RNA interference agents targeting KRAS, to reduce KRAS levels in cells by administering a therapeutically effective amount, optionally combined with other agents, to modulate KRAS expression and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for KRAS-related diseases, then treatment options are limited, but effectiveness is insufficient due to lack of direct KRAS targeting
Solution Approach 1:
The patent uses RNAi agents as intermediaries to indirectly target KRAS protein. Instead of directly inhibiting KRAS with small molecules or antibodies, the invention employs double-stranded RNA that triggers cellular machinery to degrade KRAS mRNA, thereby reducing KRAS protein levels. This intermediary approach overcomes the limitations of direct targeting methods.
Solution Approach 2:
The patent replaces conventional pharmacological mechanisms (small molecule inhibitors, monoclonal antibodies) with a biological mechanism (RNA interference). By substituting chemical/biological agents that work through different molecular mechanisms, the invention achieves KRAS inhibition through mRNA degradation rather than direct protein binding, expanding treatment versatility.
2Reliability
If RNAi agents are designed to specifically target KRAS mRNA, then KRAS protein production is reduced, but achieving sufficient mRNA degradation efficiency is challenging
Solution Approach 1:
The patent optimizes multiple parameters of the RNAi agents including nucleotide sequence composition, strand length, GC content, and chemical modifications. By systematically adjusting these parameters, the invention enhances both the specificity and efficiency of mRNA degradation while minimizing off-target effects, thereby resolving the contradiction between degradation efficiency and precision.
Solution Approach 2:
The patent employs chemically modified nucleotides and conjugated structures in the RNAi agents. These composite molecular structures combine natural RNA elements with synthetic modifications to enhance stability, cellular uptake, and degradation efficiency while maintaining sequence-specific targeting of KRAS mRNA.
3Reliability
If high doses of RNAi agents are administered to ensure therapeutic effect, then KRAS levels are effectively reduced, but off-target effects and toxicity increase
Solution Approach 1:
The patent designs RNAi agents with highly specific sequences that match only KRAS mRNA and employs chemical modifications that enhance local stability and binding affinity. This localized optimization of sequence specificity and molecular properties ensures potent KRAS inhibition at lower doses, reducing off-target effects and toxicity while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively reduce KRAS mRNA levels, leading to decreased KRAS protein production, thereby inhibiting tumor growth and ameliorating KRAS-related diseases.
Implementation Method 1
RNAi agents, specifically double-stranded RNA interference agents targeting KRAS, to reduce KRAS levels in cells
Data Source
AI summary
The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.